Evidence map›Paper›PMID 39220698›Full record

ArticleACS central science2024

A Novel Prodrug Strategy Based on Reversibly Degradable Guanidine Imides for High Oral Bioavailability and Prolonged Pharmacokinetics of Broad-Spectrum Anti-influenza Agents.

Yujeong Jung, Soo Bin Ahn, Taeyang An, Hyeon-Min Cha, Minjae Kim, Hyunjin Cheon, Yejin Jang, Haemi Lee, Byungil Kim, Meehyein Kim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yujeong JungDepartment of Chemistry, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Soo Bin AhnInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
Taeyang AnDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States.ORCID https://orcid.org/0000-0002-8802-6007
Hyeon-Min ChaInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
Minjae KimDepartment of Chemistry, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Hyunjin CheonDepartment of Chemistry, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Yejin JangInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
Haemi LeeInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.ORCID https://orcid.org/0000-0002-7866-4945
Byungil KimInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.ORCID https://orcid.org/0000-0002-1743-2657
Meehyein KimInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.ORCID https://orcid.org/0000-0002-2851-5298
Yan LeeDepartment of Chemistry, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea.ORCID https://orcid.org/0000-0003-2498-1301

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present orally administrable prodrugs (

Identifiers

PMID39220698
PMCPMC11363325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.